Management of Intravascular Hemolysis and Bleeding

Introduction to Management Approaches

The American College of Cardiology and other guideline societies recommend that intravascular hemolysis requires treatment of the underlying hemolytic process and prevention of complications, while bleeding requires hemostatic support with blood products and addressing the source of hemorrhage 1, 2

The American Society of Hematology recommends maintaining platelet count >50×10⁹/L through platelet transfusions for active bleeding with coagulopathy 1, 2, 4
Administer 15-30 mL/kg of fresh frozen plasma (FFP) for prolonged coagulation times in bleeding patients with coagulopathy 1, 2, 4
Replace fibrinogen if <1.5 g/L persists despite FFP using cryoprecipitate (2 units) or fibrinogen concentrate for bleeding patients with coagulopathy 1, 2, 4
Treat the underlying cause of bleeding, as addressing the root cause is fundamental in managing bleeding and DIC 2, 5

In cancer-associated bleeding with DIC, initiate appropriate cancer therapy (chemotherapy, surgery, radiation) immediately 2
Avoid routine antifibrinolytic agents (tranexamic acid) in most bleeding scenarios, as they are not recommended in DIC and may increase thrombotic events 5
Recombinant FVIIa is not recommended for routine use in bleeding due to thrombotic risks and lack of controlled trial evidence 5
External ventricular drainage with intraventricular fibrinolysis decreases mortality (22.4% vs 40.9% without fibrinolysis) and improves functional outcomes in intraventricular hemorrhage 6, 7

Do not use prophylactic transfusions based solely on laboratory values in bleeding patients without active hemorrhage or high bleeding risk 4
Do not use antifibrinolytics routinely, as they may be deleterious except in specific hyperfibrinolytic scenarios 5
Recognize that transfused product half-life is very short in DIC with vigorous coagulation activation 1, 2